



12111 1815 18X 620 11274875 10/21/94 1804
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: 6200
EVANS ET AL.

Serial No.: 08/244,857

Filed: June 14, 1994

For: MEANS FOR THE MODULATION
OF PROCESSES MEDIATED BY
RETINOID RECEPTORS AND
COMPOUNDS USEFUL THEREFOR

BOX SEQUENCE

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

PATENT
Our Docket: P41 9755

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner of Patents and Trade
marks, Washington, D. C. 20231, on 10/12/94

BY Steph E. Reiter Date
Stephen E. Reiter Reg. No. 31,192

10/12/94 Date of Signature

RECEIVED

OCT 21 1994

GROUP 1800

COMMUNICATION

Sir:

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES mailed September 12, 1994, the
following are provided:

- (1) a copy of the NOTICE;
- (2) a copy of the sequence information in computer readable
form;
- (3) a Preliminary Amendment with replacement pages 52-53;
and
- (4) a statement under 37 CFR §1.821 (f) and (g).

Respectfully submitted,

Date: 10/12/94

Steph E. Reiter
Stephen E. Reiter
Registration No. 31,192
Telephone: (619) 546-4737
Facsimile: (619) 546-9392

PRETTY, SCHROEDER,
BRUEGEMANN & CLARK
444 South Flower Street, Suite 2000
Los Angeles, California 90071



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	30	30	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
--------------------	----	----	-------------	-----------------------	------------------------

08/244,857 06/14/94 EVANS

R F41 9755

03A1/0912

STEPHEN E. REITER
PRETTY, SCHROEDER, BRUEGEMANN & CLARK
444 SOUTH FLOWER STREET
SUITE 2000
LOS ANGELES, CALIFORNIA 90071

RECEIVED

OCT 21 1994

0000 GROUP 1800

DATE MAILED: 09/12/94

**NOTICE TO FILE MISSING PARTS OF APPLICATION
FILING DATE GRANTED**

An Application Number and Filing Date have been assigned to this application. However, the items indicated below are missing. The required items and fees identified below must be timely submitted **ALONG WITH THE PAYMENT OF A SURCHARGE** for items 1 and 3-6 only of \$_____ for large entities or \$_____ for small entities who have filed a verified statement claiming such status. The surcharge is set forth in 37 CFR 1.16(e).

If all required items on this form are filed within the period set below, the total amount owed by applicant as a large entity, small entity (verified statement filed), is \$_____.

Applicant is given **ONE MONTH FROM THE DATE OF THIS LETTER, OR TWO MONTHS FROM THE FILING DATE** of this application, **WHICHEVER IS LATER**, within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).


1. The statutory basic filing fee is: missing insufficient. Applicant as a large entity small entity, must submit \$_____ to complete the basic filing fee.
2. Additional claim fees of \$_____ as a large entity, small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
3. The oath or declaration:
 is missing.
 does not cover items omitted at time of execution.
4. The oath or declaration does not identify the application to which it applies. An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
5. The signature to the oath or declaration is: missing; a reproduction; by a person other than the inventor or a person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
6. The signature of the following joint inventor(s) is missing from the oath or declaration:

An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.

7. The application was filed in a language other than English. Applicant must file a verified English translation of the application and a fee of \$_____ under 37 CFR 1.17(k), unless this fee has already been paid.
8. A \$_____ processing fee is required for returned checks. (37 CFR 1.21(m)).
9. Your filing receipt was mailed in error because check was returned without payment.
10. The application does not comply with the Sequence Rules. See attached Notice to Comply with Sequence Rules 37 CFR 1.821-1.825.
11. Other.

Direct the response and any questions about this notice to John H. Hallinan, Application Processing Division, Special Processing and Correspondence Branch (703) 308-1202.

Any of this notice MUST be returned with



Application No. 08/244 857

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other: _____

Applicant must provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.

PATENT
Our Docket: P41 9755

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)
EVANS ET AL.)
Serial No.: 08/244,857)
Filed: June 14, 1994)
For: MEANS FOR THE MODULATION)
OF PROCESSES MEDIATED BY)
RETINOID RECEPTORS AND)
COMPOUNDS USEFUL THEREFOR)

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner of Patents and Trade
marks, Washington, D. C. 20231, on 10/12/94

BY Steph E. Reiter
Stephen E. Reiter Reg. No. 31,192
10/12/94
Date of Signature

RECEIVED

BOX SEQUENCE
Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

OCT 21 1994

GROUP 1800

STATEMENT UNDER 37 C.F.R. § 1.821(f) and (g)

Sir:

I hereby state, as required by 37 C.F.R. §1.821(f),
that the content of the paper and computer readable copy of the
Sequence Listing, submitted in accordance with 37 CFR § 1.821(c)
and (e), respectively, are the same.

I hereby state, as required by 37 C.F.R. § 1.821 (g),
that the enclosed submission includes no new matter.

Respectfully submitted,

Date: 10/12/94

Steph E. Reiter
Stephen E. Reiter
Registration No. 31,192
Telephone: (619) 546-4737
Facsimile: (619) 546-9392

PRETTY, SCHROEDER,
BRUEGEMANN & CLARK
444 South Flower Street, Suite 2000
Los Angeles, California 90071